Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-08-08
2003-05-06
Nguyen, Dave T. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093200, C435S320100, C435S455000
Reexamination Certificate
active
06559130
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
The present invention relates to the use of an epithelium-destroying agent to destroy the epithelium of an exocrine gland, particularly the mammary gland, in the prophylactic and therapeutic treatment of disease, in particular cancer.
BACKGROUND OF THE INVENTION
Exocrine glands are glands that release a secretion external to or at the surface of an organ by means of a canal or duct. Examples of exocrine glands include, among others, the mammary glands, prostate, liver, gall bladder, pancreas, kidneys, sweat glands, and salivary glands. Cancers of exocrine glands pose a major health problem, frequently resulting in death. Currently, cancers of the breast and prostate are among the leading causes of death among women and men, respectively.
The mature human breast comprises from six to nine major ducts, which emanate from the nipple, serially branch into ducts and terminate in lobuloalveolar structures (Russo et al., Lab. Invest. 62(3): 244-278 (1990)). This branching network of ducts is composed of epithelial cells in a supporting matrix of connective tissue and endothelial cells.
Tissues removed from the human female breast during surgery and autopsy have been examined in numerous studies directed to the nature and site of origin of neoplastic growth. Subgross sampling and histological confirmation have enabled pathological characterization of entire breasts, leading to the postulation of the existence of four major possible sites of origin of mammary carcinomas, namely ducts, terminal ducts, ductules, and acini (Russo et al., supra). Ductal origin is supported by the presence of more extensive epithelial proliferations, which are presumed to be preneoplastic, in surgically removed cancerous breasts as compared to nonmalignant breasts removed during autopsies (Russo et al., supra).
With a cumulative lifetime risk of a woman developing breast cancer estimated to be 1 in 9, there is an urgent need to develop therapeutic methods of treatment that are more effective, less invasive and accompanied by fewer side effects and prophylactic methods of treatment that are more effective than increased and intensified physical monitoring and far less extreme than radical mastectomy. In spite of the recent discovery of the heritable breast cancer susceptibility loci, BRCA1 (Miki et al., Science 266: 66-71 (1994)) and BRCA2, and other cancer susceptibility loci, and the increasing ability of physicians to identify women with elevated breast cancer risk, prophylactic methods are still currently limited to physical monitoring and prophylactic mastectomy.
In view of the above, it is an object of the present invention to provide a method of locally treating an exocrine gland prophylactically for disease. It is another object of the present invention to provide a method of locally treating an exocrine gland, in particular the mammary gland, prophylactically for cancer. Another object of the present invention is to provide a method of locally treating an exocrine gland therapeutically for disease. Yet another object of the present invention is to provide a method of locally treating a mammary gland therapeutically for cancer. Still yet another object of the present invention is to provide a method of locally treating a mammary gland both therapeutically and prophylactically for cancer. These and other objects and advantages, as well as additional inventive features, will become apparent from the detailed description provided herein.
SUMMARY OF THE INVENTION
The present invention provides prophylactic and therapeutic methods of treating the ductal epithelium of an exocrine gland, in particular the mammary gland, for disease, in particular cancer. The method comprises contacting the ductal epithelium of the exocrine gland, in particular the mammary gland, with an epithelial-destroying agent. The ductal epithelium is preferably contacted with the agent by ductal cannulation. The epithelium-destroying agent is preferably a vector comprising a thymidine kinase gene, which is used in combination with ganciclovir (GCV), which can be systemically administered. Another preferred epithelium-destroying agent is a vector comprising a hypoxanthine phosphoribosyl transferase (HPRT) gene, which is used in combination with hypoxanthine aminopterin thymidine (HAT) nucleotide, which can be systemically administered. Also preferred as an epithelium-destroying agent is a vector comprising a gene, which, upon transformation of a cell of the ductal epithelium and expression therein, induces apoptosis or death of the transformed cell. A preferred apoptosis-inducing gene is bclxs. Other preferred epithelial-destroying agents include a cytolytic virus, such as Vaccinia virus, and ethanol. The preceding methods can additionally comprise contacting the ductal epithelium with a cytokine or hematopoietic growth factor, such as GM-CSF. Also provided by the present invention is a method of treating the ductal epithelium of a mammary gland both therapeutically and prophylactically for cancer. The combined therapeutic/prophylactic method comprises treating the mammary gland therapeutically by surgery, radiation and/or chemotherapy and contacting the ductal epithelium of the mammary gland, either concomitantly or subsequently, with an epithelium-destroying agent, which does not specifically target cancerous cells. The combined therapeutic/prophylactic method can additionally comprise contacting the ductal epithelium with a cytokine or hematopoietic growth factor, such as GM-CSF.
REFERENCES:
patent: 5149527 (1992-09-01), Weisenthal
patent: 5215904 (1993-06-01), Gould et al.
patent: 5304489 (1994-04-01), Rosen
patent: 5383849 (1995-01-01), Johlin
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5651964 (1997-07-01), Hung et al.
patent: 5662896 (1997-09-01), Barber et al.
patent: 5744133 (1998-04-01), Lathe et al.
patent: 5747469 (1998-05-01), Roth et al.
patent: 5780009 (1998-07-01), Karatzas
patent: 5833975 (1998-11-01), Paoletti et al.
patent: 5837693 (1998-11-01), German et al.
patent: 5858365 (1999-01-01), Faller
patent: 5866550 (1999-02-01), Frisch
patent: 0 118365 (1984-09-01), None
patent: 0 352722 (1990-01-01), None
patent: 0 657174 (1995-06-01), None
patent: WO93/02556 (1993-02-01), None
patent: WO94/09160 (1994-04-01), None
patent: WO94/26915 (1994-11-01), None
Meng et al., Tumor suppressor genes as targets for cancer gene therapy, 1999, Gene Therapy of Cancer, pp. 3-20.*
Tait et al., Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vecotr stability, 1999, Clinical Cancer Research, vol. 5, pp. 1708-1714.*
Gunzburg et al., Virus vector design in gene therapy, 1995, Molecular Medicine Today, vol. 1, pp. 410-417.*
Verma et al., Gene therapy-promises, problems and prospects, 1997, Nature, vol. 389, pp. 239-242.*
Tanigawa et al., Gene gun application in the generation of effector T cells for adoptive immunotherapy, 2000, Cancer Immunol Immunother, vol. 48, pp. 635-643.*
Yeung et al. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor, 1994, Cancer, vol. 73, pp. 1960-1970.*
Majumdar et al., Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer, 2000, Cancer Gene Therapy, vol. 7, pp. 1086-1099.*
O'Shaughnessy et al., A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy andescherichia coli-derived granulocytemacrophage colony-stimulating factor . . . , 1994, Annals of Oncology, vol. 5, pp. 70-716.*
Pinedo et al., Biological concepts of prolonged neoadjuvant treatment plus GM-CSF in locally advanced tumors, 2000, the Oncologist, vol. 5, 497-500.*
Ariyama et al. (Medline, AN: 91185944, International J. Pancreat, 7, 1-3,37-47, abstract, 1990).
Berchem et al., Cancer Research, 55:735-738 (Feb. 15, 1995).
Bieche et al., Cancer Research, 54:4274-4276 (Aug. 15, 1994).
Chen et al., Proc. Natl. Acad. Sci. USA, 91:3054-3057 (Apr. 19
Johns Hopkins University School of Medicine
Leydig , Voit & Mayer, Ltd.
Nguyen Dave T.
LandOfFree
Destruction of the epithelium of an exocrine gland in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Destruction of the epithelium of an exocrine gland in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Destruction of the epithelium of an exocrine gland in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3024415